Evidence map›Paper›PMID 35233527›Full record

ArticleBrain communications2022

Syndapin-2 mediated transcytosis of amyloid-β across the blood-brain barrier.

Diana M Leite, Mohsen Seifi, Lorena Ruiz-Perez, Filomain Nguemo, Markus Plomann, Jerome D Swinny, Giuseppe Battaglia

Open access · goldAbstract read
In one paragraph

Article in Brain communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

Diana M LeiteDepartment of Chemistry, University College London, London, UK.
Mohsen SeifiLeicester School of Pharmacy, Faculty of Health and Life Sciences, De Montfort University, Leicester, UK.
Lorena Ruiz-PerezDepartment of Chemistry, University College London, London, UK.
Filomain NguemoInstitute for Neurophysiology, Faculty of Medicine, University of Cologne, Cologne, Germany.
Markus PlomannInstitute of Biochemistry, Faculty of Medicine, University of Cologne, Cologne, Germany.
Jerome D SwinnySchool of Pharmacy and Biomedical Sciences, University of Portsmouth, UK.
Giuseppe BattagliaDepartment of Chemistry, University College London, London, UK.ORCID https://orcid.org/0000-0001-6509-5627
University College London · GBUniversity of Cologne · DEDe Montfort University · GBInstitució Catalana de Recerca i Estudis Avançats · ESUniversity of Portsmouth · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A deficient transport of amyloid-β across the blood-brain barrier, and its diminished clearance from the brain, contribute to neurodegenerative and vascular pathologies, such as Alzheimer's disease and cerebral amyloid angiopathy, respectively. At the blood-brain barrier, amyloid-β efflux transport is associated with the low-density lipoprotein receptor-related protein 1. However, the precise mechanisms governing amyloid-β transport across the blood-brain barrier, in health and disease, remain to be fully understood. Recent evidence indicates that the low-density lipoprotein receptor-related protein 1 transcytosis occurs through a tubulation-mediated mechanism stabilized by syndapin-2. Here, we show that syndapin-2 is associated with amyloid-β clearance via low-density lipoprotein receptor-related protein 1 across the blood-brain barrier. We further demonstrate that risk factors for Alzheimer's disease, amyloid-β expression and ageing, are associated with a decline in the native expression of syndapin-2 within the brain endothelium. Our data reveals that syndapin-2-mediated pathway, and its balance with the endosomal sorting, are important for amyloid-β clearance proposing a measure to evaluate Alzheimer's disease and ageing, as well as a target for counteracting amyloid-β build-up. Moreover, we provide evidence for the impact of the avidity of amyloid-β assemblies in their trafficking across the brain endothelium and in low-density lipoprotein receptor-related protein 1 expression levels, which may affect the overall clearance of amyloid-β across the blood-brain barrier.

Indexed as

Alzheimer’s diseaseamyloid-βblood–brain barrierSyndapin-2tubular transcytosis

Identifiers

PMID35233527
PMCPMC8882007
OpenAlexW4213281091

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.